Bimatoprost Ophthalmic Solution for Effective Glaucoma Management
| Product dosage: 0.3mg | |||
|---|---|---|---|
| Package (num) | Per bottle | Price | Buy |
| 1 | $60.27 | $60.27 (0%) | 🛒 Add to cart |
| 2 | $50.22 | $120.54 $100.45 (17%) | 🛒 Add to cart |
| 3 | $43.53 | $180.81 $130.58 (28%) | 🛒 Add to cart |
| 4 | $42.69 | $241.08 $170.76 (29%) | 🛒 Add to cart |
| 5 | $40.18 | $301.34 $200.90 (33%) | 🛒 Add to cart |
| 6 | $38.51 | $361.61 $231.03 (36%) | 🛒 Add to cart |
| 7 | $37.31 | $421.88 $261.16 (38%) | 🛒 Add to cart |
| 8 | $36.41 | $482.15 $291.30 (40%) | 🛒 Add to cart |
| 9 | $34.60 | $542.42 $311.39 (43%) | 🛒 Add to cart |
| 10 | $33.15
Best per bottle | $602.69 $331.48 (45%) | 🛒 Add to cart |
Synonyms | |||
Bimatoprost ophthalmic solution is a prostaglandin analog specifically formulated to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. As a first-line therapeutic option, it works by increasing the outflow of aqueous humor, thereby providing consistent and significant IOP reduction. Its once-daily dosing regimen supports patient adherence, while its well-established efficacy profile makes it a cornerstone in modern glaucoma treatment protocols. This medication represents a critical tool in preserving visual field and preventing optic nerve damage in chronic ocular conditions.
Features
- Contains 0.03% bimatoprost as the active pharmaceutical ingredient
- Presented as a sterile, isotonic, buffered ophthalmic solution
- pH-balanced formulation to minimize ocular surface irritation
- Preservative-free single-dose containers available for sensitive patients
- Packaged in 2.5 mL or 5 mL opaque bottles with controlled-drop dispensers
- Storage stability of 24 months unopened, 28 days after opening
Benefits
- Achieves up to 25-33% reduction in intraocular pressure from baseline
- Provides 24-hour IOP control with single daily administration
- Demonstrates consistent efficacy across diverse patient populations
- Helps slow progression of glaucomatous visual field loss
- May enhance eyelash growth as a secondary beneficial effect
- Compatible with most concomitant ocular medications when properly timed
Common use
Bimatoprost ophthalmic solution is primarily indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It is frequently prescribed as monotherapy but may also be used adjunctively with other IOP-lowering medications when additional pressure control is required. Clinical studies have demonstrated its effectiveness in various demographic groups, including elderly patients and those with pigmentary or pseudoexfoliative glaucoma variants.
Dosage and direction
The recommended dosage is one drop in the affected eye(s) once daily in the evening. Administration frequency exceeding once daily may decrease the IOP-lowering effect. Patients should be instructed to remove contact lenses prior to application and wait at least 15 minutes before reinsertion. Proper administration technique includes gentle eyelid closure, nasolacrimal occlusion, and punctal compression for 1-2 minutes to minimize systemic absorption.
Precautions
Patients should be monitored for periocular skin pigmentation changes, iris pigmentation alterations, and eyelash modifications, which may be permanent. Caution is advised in patients with intraocular inflammation, macular edema risk factors, or corneal epithelial defects. Regular ophthalmologic examinations are recommended to monitor intraocular pressure response and assess for potential adverse effects. Patients should be advised regarding potential gradual lightening of iris color, particularly in those with mixed-color irides.
Contraindications
Bimatoprost is contraindicated in patients with known hypersensitivity to bimatoprost or any component of the formulation. Its use should be avoided in patients with active intraocular inflammation and in those with angle-closure glaucoma unless accompanied by iridotomy. Contraindication extends to patients with suspected viral, fungal, or bacterial ocular infections requiring appropriate antimicrobial therapy.
Possible side effects
The most frequently reported ocular adverse reactions (approximately 15-45% of patients) include conjunctival hyperemia, growth of eyelashes, and ocular pruritus. Between 3-10% of patients may experience ocular dryness, visual disturbance, foreign body sensation, eye pain, pigmentation of the periocular skin, blepharitis, cataract, and superficial punctate keratitis. Less than 3% of patients report eyelid erythema, allergic conjunctivitis, asthenopia, conjunctival edema, intraocular inflammation, and iritis. Systemic side effects are uncommon but may include headaches (approximately 5%) and occasional reports of dizziness or respiratory symptoms.
Drug interaction
Although minimal systemic absorption occurs with proper ocular administration, potential interactions may exist with other prostaglandin analogs. Concurrent use with pilocarpine may reduce efficacy due to formulation incompatibility and should be administered at least 5 minutes apart. No clinically significant interactions have been observed with systemic medications, though theoretical interactions with other prostamides cannot be entirely excluded. Patients using multiple topical ophthalmic medications should administer them at least 5 minutes apart.
Missed dose
If a dose is missed, patients should apply the solution as soon as possible on the same day. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped, and the regular dosing schedule resumed. Patients should never apply double doses to compensate for a missed administration. Consistent evening administration helps maintain stable therapeutic concentrations and optimal IOP control.
Overdose
Ocular overdose may be flushed from the eye(s) with warm tap water. Systemic overdose is unlikely due to minimal absorption but might theoretically cause prostaglandin-like effects including headache, flushing, nausea, and hypotension. Symptomatic and supportive care is recommended. Medical attention should be sought if accidental ingestion occurs, though the low concentration in ophthalmic preparations makes significant systemic effects improbable.
Storage
Store unopened bottles at controlled room temperature 15°-30°C (59°-86°F). Protect from light and excessive heat. Once opened, the solution should be used within 28 days. Keep the container tightly closed when not in use. Do not freeze. Keep out of reach of children and pets. Discard any solution that becomes discolored or contains particles.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Treatment decisions should be made exclusively by qualified healthcare professionals based on individual patient circumstances. Patients should consult their ophthalmologist regarding appropriate use, potential risks, and monitoring requirements. The full prescribing information should be reviewed before initiating therapy.
Reviews
Clinical studies involving over 2,800 patients demonstrated bimatoprost’s consistent efficacy, with 60-70% of patients achieving target IOP levels below 18 mmHg. Long-term extension studies show maintained efficacy for up to 36 months of continuous treatment. Patient satisfaction surveys indicate high adherence rates due to once-daily dosing and generally favorable tolerability profile compared to older glaucoma medications. Ophthalmologists frequently report reliable IOP control and preservation of visual fields in compliant patients.